<DOC>
	<DOCNO>NCT00007202</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness stavudine ( d4T ) , didanosine ( ddI ) , BMS-232632 give early course HIV infection . Acute HIV infection may develop patient expose HIV virus . Following infection , viral load ( level HIV blood ) rise rapidly next day week . It known best treatment patient early HIV infection . Researchers believe patient may respond well strong early treatment . A combination consist enteric-coated didanosine ( ddI-EC ) , stavudine ( d4T ) , HIV-1 protease inhibitor , BMS-232632 , test .</brief_summary>
	<brief_title>Safety Effectiveness Three-Drug Combination Treatment Recently Infected Converted HIV Patients</brief_title>
	<detailed_description>Acute primary HIV-1 infection ( PHI ) follow exposure HIV-1 virus result rapid rise plasma viremia within day 1 3 week . Individuals acute PHI early HIV-1 infection represent potentially unique patient population evaluate potent antiretroviral therapy degree viral heterogeneity fact immunologic disruption likely low later stage HIV-1 disease . The optimal treatment acute PHI unknown . This study evaluate regimen consist enteric-coated didanosine ( ddI-EC ) , stavudine ( d4T ) , HIV-1 protease inhibitor , BMS-232632 . Patients enrol Group I Group II may participate substudies . Patients Group I receive ddI-EC , d4T , BMS-232632 daily 52 week . Clinical , virologic , immunologic evaluation perform Days 2 , 7 , 14 , 21 , 28 , every 4 week Week 24 , every 8 week thereafter Week 48 . Based laboratory result Week 48 visit , decision make Week 52 whether continue study medication additional 52 week . Evaluation schedule patient enrol substudies may different . Group II patient elect receive antiretroviral treatment follow natural history disease group compare patient Group I . They follow accord schedule evaluation enrol Group I , unless otherwise specify part participation substudies . All patient follow study 8-week interval total duration 104 week ( 2 year ) . HIV measure plasma tissue determine reduction replication duration least 48 week . The 3 substudies patient may participate AI-03-006 , Lymphoid Tissue Substudy ; AI-03-007 , Immunology Substudy cytolytic co-stimulatory marker , T-cell repertoire , cytokine chemokine elaboration ; AI-03-008 , Viral Dynamics Diversity Substudy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Have early HIV infection show recent seroconversion ( go HIVnegative HIVpositive ) . Are least 18 year old . Agree 2 barrier method birth control , heterosexually active men woman , study 3 month . Exclusion Criteria Patients eligible study : Have receive prior antiretroviral therapy . Have receive interferon , interleukin , colonystimulating factor , radiation , cytotoxic chemotherapy , HIV vaccine within 30 day prior study entry . Have experimental therapy within 30 day prior study entry . Are pregnant breastfeeding . Patients eligible Group I : Have pancreatitis ( inflammation pancreas ) . Have receive alpha tocopherol ( vitamin E ) , amiodarone , astemizole , carbamazepine , cisapride , ergotamine/diergotamine , estrogens , fluvastatin , glucocorticoid , itraconazole , ketoconazole , midazolam , phenobarbital , phenytoin , quinidine , rifampin , rifabutin , sildenafil , statin drug ( simvastatin , pravastatin , atorvastatin ) use reduction triglyceride cholesterol level , terfenadine , triazolam , warfarin within 14 day study entry . Have receive chloramphenicol , cisplatin , clioquinol , dapsone , diphenylhydantoin , disulfiram , ethionamide , glutethimide , gold , hydralazine , isoniazid , metronidazole , pyridoxine , sodium cyanate , thalidomide , vincristine , zalcitabine within 30 day study entry . In certain case , patient take drug may still eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Virus Replication</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Sensitivity Specificity</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword>
	<keyword>Acute Infection</keyword>
</DOC>